InvestorsHub Logo
Followers 120
Posts 20416
Boards Moderated 0
Alias Born 06/13/2011

Re: CaptBeer post# 424074

Wednesday, 05/08/2024 6:50:53 PM

Wednesday, May 08, 2024 6:50:53 PM

Post# of 424687
Because Dr Ketchum probably knows this already ...and knows AMRN will not spend time and $ on pursuing this since for one thing they would need to prove it better than an EPA/DHA combination .

A network meta-analysis study provided compelling evidence that high-dosage EPA/DHA (omega-3 fatty acid) supplementation can be considered a first-choice treatment for migraine prophylaxis.
Another study found that high-dosage omega-3 fatty acids, including EPA/DHA, outperformed existing pharmacological options for migraine prophylaxis. The researchers concluded that EPA/DHA supplementation can be considered as a first-choice treatment for migraine prevention.
A review article discussed the potential therapeutic role of omega-3 fatty acids, including EPA, in the treatment of migraine through their anti-inflammatory effects. The review highlighted several clinical studies examining the use of omega-3 fatty acids, either alone or in combination with other substances, for migraine treatment.
In summary, the search results indicate that multiple studies have investigated the use of EPA, either alone or as part of omega-3 fatty acid supplementation, for the treatment and prophylaxis of migraine.



Kiwi
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News